Array Biopharma to report 3Q earnings April 29
Last Updated: 13:05 April 24, 2014
Chief executive Ron Squarer and chief financial officer Michael Carruthers will lead the call that begins at 7 a.m. Mountain time.
To listen in, call 1-800-708-4540 toll-free, of 1-847-619-6397 for a toll. Pass code is 36946658. A webcast, including replay and conference call slides can be accessed on line here.
Also, following the recent announcement by Novartis and GlaxoSmithKline that they have entered into a definitive agreement to exchange certain assets, Array reports that Novartis has indicated that it will continue to honor its obligations under the Array-Novartis agreement relating to binimetinib (MEK162), including obligations to support ongoing clinical trials.
In April 2010, Array entered into an agreement under which Novartis received exclusive worldwide rights to binimetinib. If Novartis' binimetinib development and commercialization rights are returned to Array, Novartis is required to provide support for ongoing clinical studies as specified in that agreement.
More breaking news...
InDevR receives $3 million SBIR grant
SCL drops 'Exempla' from hospitals names
Ten companies in region received VC in 2Q
The move is part of a rebranding effort for
Boulder-based Orbotix Inc.,